Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Icosavax headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $19.8B in funding across 84 round(s). With a team of 11-50 employees, Icosavax is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Icosavax, raised $6.5M. Discover more about their projects, partnerships, and impact on our platform.